Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Summary

This is a study to assess the safety of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid tumors, and determine preliminary efficacy of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable Triple Negative Breast Cancer (TNBC). The structure for the study is a single arm, non-randomized, open-label, multicenter trial with no control group. The study will be conducted at up to 11 sites, with up to 40 evaluable patients

Timeline

Start

2014-01

Primary completion

2017-12

Completion

2017-12

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “Preliminary efficacy results in Phase 1/2 trial of mifepristone plus eribulin (Eisai’s Halaven®) to treat triple-negative breast cancer (TNBC) indicate combination is active” corcept.com ↗

Drugs

Indications